Sugi Predict

Sugi Predict / Compounds / SCHEMBL2107582

SCHEMBL2107582

SCHEMBL2107582

COc1ccc(C(=O)/C=C/N(C)C)c(O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 7/20 0.65
▸ MAPT P10636 5/20 0.65
▸ APP P05067 5/20 0.65
▸ MAPK1 P28482 4/20 0.65
▸ LMNA P02545 3/20 0.65
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ CYP3A4 P08684 3/20 0.65
▸ CYP2C19 P33261 1/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.65
▸ MAOB P27338 3/20 0.64
▸ MAOA P21397 2/20 0.64
▸ NPC1 O15118 3/20 0.62
▸ RAB9A P51151 3/20 0.62
▸ RECQL P46063 1/20 0.62
▸ ATM Q13315 1/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ ALDH1A1 P00352 3/20 0.60
▸ HPGD P15428 3/20 0.60
▸ CTSL P07711 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29690463 1.00 ABCG2 (0.65) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL2107584 1.00 ABCG2 (0.65) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL30904861 1.00 ABCG2 (0.65) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL12722749 1.00 ABCG2 (0.65) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL29076154 0.88 MAPT (0.60) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL28749229 0.88 MAPT (0.60) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL5808359 0.85 ABCG2 (0.67) ABCG2MAPTMAPK1LMNAMEN1
SCHEMBL5808361 0.85 ABCG2 (0.67) ABCG2MAPTMAPK1LMNAMEN1
SCHEMBL29246799 0.85 MAPT (0.60) ABCG2MAPTAPPMAPK1LMNA
SCHEMBL12722743 0.85 ABCG2 (0.67) ABCG2MAPTMAPK1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005593-A Preparation method of 2, 3-disubstituted chromone compound 昆明理工大学 2024-05-10 — — CN disclosed
US-20220133894-A1 BISPHOSPHONATE-LINKED COMPOUNDS OREGON HEALTH & SCIENCE UNIVERSITY (US) 2022-05-05 — — US disclosed
WO-2020163637-A1 BISPHOSPHONATE-LINKED COMPOUNDS OREGON HEALTH & SCIENCE UNIVERSITY (US) 2020-08-13 — — WO disclosed
US-8158810-B2 ALDH-2 inhibitors in the treatment of addiction GILEAD SCIENCES, INC. (US) 2012-04-17 — — US disclosed
US-8158810-B2 ALDH-2 inhibitors in the treatment of addiction GILEAD SCIENCES, INC. (US) 2012-04-17 — — US disclosed
US-8158810-B2 ALDH-2 inhibitors in the treatment of addiction GILEAD SCIENCES, INC. (US) 2012-04-17 — — US disclosed
EP-2254878-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION Gilead Palo Alto, Inc. (US) 2010-12-01 — — EP disclosed
EP-2231149-A2 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS CV Therapeutics Inc. (US) 2010-09-29 — — EP disclosed
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2009-08-20 — — US disclosed
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2009-08-20 — — US disclosed
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS AMYGDALA NEUROSCIENCES, INC. 2009-05-14 — — US disclosed
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS AMYGDALA NEUROSCIENCES, INC. 2009-05-14 — — US disclosed
EP-2046769-A2 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION CV THERAPEUTICS, INC. (US) 2009-04-15 — — EP disclosed
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-08-28 — — US disclosed
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-08-28 — — US disclosed
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-08-28 — — US disclosed
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-02-07 — — US disclosed
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-02-07 — — US disclosed
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-02-07 — — US disclosed
WO-2008014497-A2 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION CV THERAPEUTICS, INC. (US) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 ABCG2 655/4885MAPT 1815/4885APP 4746/4885
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 ABCG2 655/4885MAPT 1815/4885APP 4746/4885
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION ALDH1A1, ADH1A, ALDH3A1 ABCG2 518/4885MAPT 1778/4885APP 4757/4885
US-20220133894-A1 BISPHOSPHONATE-LINKED COMPOUNDS BPGM, P2RY6, TRPV6 ABCG2 27/4885MAPT 2110/4885APP 4342/4885
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS ALDH2, ALDH1A2, ALDH1A1 ABCG2 1120/4885MAPT 2549/4885APP 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.